← FDA DRUG APPROVALS

FDA NDA · NDA019857

CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER

Sponsor: BAYER HLTHCARE

APPLICATION
NDA019857
TYPE
NDA
ORIGINAL APPROVAL
1990-12-26
LATEST ACTION
2022-03-25
ROUTE
INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Discontinued

Products

CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER · ReferenceDiscontinued
CIPROFLOXACIN 400MG/200ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE · INJECTION
CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER · ReferenceDiscontinued
CIPROFLOXACIN 200MG/100ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE · INJECTION

Approval history

2022-03-25Labeling · Supplement 73 · standardLabelAP
2020-05-08Labeling · Supplement 72 · standardLetterAP
2020-03-05Labeling · Supplement 70 · standardLabelAP
2019-05-03Labeling · Supplement 69 · standardLetterAP
2018-10-18Labeling · Supplement 68 · standardLabelAP
2017-07-26Labeling · Supplement 66 · standardLetterAP
2016-07-26Labeling · Supplement 65 · standardLabelAP
2015-03-19Labeling · Supplement 64 · standardLetterAP
2015-02-02Efficacy · Supplement 63 · standardLetterAP
2013-10-14Manufacturing (CMC) · Supplement 61 · standardAP
2013-08-14Labeling · Supplement 62 · 901 requiredLabelAP
2013-01-30Labeling · Supplement 60 · standardLetterAP
2011-11-15Labeling · Supplement 53 · standardLetterAP
2011-10-18Labeling · Supplement 59 · unknownLabelAP
2011-08-12Labeling · Supplement 57 · standardLabelAP
2011-08-03REMS · Supplement 58LetterAP
2011-02-25Labeling · Supplement 54 · 901 requiredLabelAP
2009-06-24Labeling · Supplement 52 · standardLetterAP
2009-04-27Labeling · Supplement 51 · standardLetterAP
2009-02-13Labeling · Supplement 50 · standardLabelAP
2008-10-03Labeling · Supplement 49 · standardLabelAP
2008-01-18Labeling · Supplement 48 · standardLetterAP
2007-06-25Labeling · Supplement 46 · standardLabelAP
2006-06-19Labeling · Supplement 42 · standardLetterAP
2005-11-09Labeling · Supplement 41 · standardReviewAP
2005-05-18Labeling · Supplement 38 · standardLetterAP
2005-01-07Efficacy · Supplement 35 · unknownLetterAP
2004-07-14Labeling · Supplement 33 · standardReviewAP
2004-07-14Labeling · Supplement 36 · standardReviewAP
2004-07-14Labeling · Supplement 34 · standardReviewAP
2004-03-25Efficacy · Supplement 31 · priorityReviewAP
2002-12-10Manufacturing (CMC) · Supplement 29 · standardAP
2002-04-17Labeling · Supplement 28LetterAP
2000-08-30Efficacy · Supplement 27 · priorityReviewAP
2000-06-28Labeling · Supplement 25 · standardAP
1999-06-09Manufacturing (CMC) · Supplement 26 · standardAP
1999-01-07Manufacturing (CMC) · Supplement 23 · standardAP
1998-11-13Manufacturing (CMC) · Supplement 22 · standardAP
1998-09-24Efficacy · Supplement 19 · standardAP
1998-09-24Efficacy · Supplement 21 · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →